ClinicalTrials.gg
Active, not recruitingNCT06410963Updated Apr 14, 2026

ReActivate: Physiotherapist Led Intervention for A Adolescents and Young Adults With Musculoskelatal Pain

An interventional study of Reactivate in Chronic Pain and Emotional Distress, sponsored by Örebro University, Sweden. Active, not recruiting at 1 site in Sweden. Open to participants aged 12 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Örebro University, Sweden · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
12 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Chronic Pain with a site in Sweden — 30 open to participants now, 37 under way, none of them phase 3. Chronic Pain · Sweden.

Planned enrollment
47th of 65
35 · median 80
Started
2024
with 6 others
No phase
61 of 88
23 open now
Primary completion
2026-11
later than 12 of 36 live
Registered
68th of 88
by date
Lead sponsor
3 of 88
Örebro University, Sweden

Among the 88 studies in Chronic Pain with a site in Sweden, this one is the 47th largest by planned enrollment of the 65 interventional ones that give a count, is one of 7 that started in 2024, is one of 61 with no phase, reaches primary completion later than 12 of the 36 other live ones, and was the 68th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

30 of the 88 studies in Chronic Pain with a site in Sweden are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 12 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Chronic Pain with a site in Sweden, or all of them as a file.
02

Study summary

Recurrent or persistent musculoskeletal pain is an alarmingly common problem among adolescents, in Sweden as well as globally. Pain often co-occur with and psychological distress and have both been shown to be predictors of sustained problems in adulthood. Adequate treatment early on in the development of problems has been shown important in order to decrease the risk of sustained problems in adulthood but available treatments have only modest effects. There is thus a need for treatment development, not in the least for (secondary) preventative purposes. The aim of this project is therefore to develop an evidence based and cost-effective secondary preventative intervention. Specifically, this project aims to develop and test a physiotherapist led treatment for adolescents with recurrent or persistent musculoskeletal pain and based upon graded exposure to physical activity and reactivation.

Read the detailed description

See description of arms and intervention.

03

Conditions studied

  • Chronic Pain
  • Emotional Distress

Browse trials for

04

Who can participate

Ages eligible
12 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 12-25
  • Persistent (consistently or weekly recurrent) musculoskeletal pain problems for ≥3 months, with pain intensity ≥2 on a numeric rating scale 0-6 (0=not at all, 6=to a great extent)
  • Presence of avoidance behaviour and/or or worry about symptoms/problems, ≥1 on a numeric rating scale 0-6 (0=not at all, 6=to a great extent); > 50 on at least one activity of the PHODA.
  • Swedish speaking and able to fill out questionnaires

Exclusion criteria

Exclusion Criteria:

  • Serious/malignant disease
  • Participation in other rehabilitation program
  • Severe mental health problems
  • Substance abuse
  • Severe learning disabilities
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
35 participants (estimated)

Study arms

  • No intervention
    No treatment waiting period

    Participants are randomized to a 7, 14 or 21 day waiting period. Daily measurements are collected throughout this period.

  • Experimental
    Reactivate

    Reactivate treatment. Daily measurements are collected throughout treatment.

    Behavioral: Reactivate

Interventions

  • BehavioralReactivate

    The study period is 84 days (12 weeks). Depending on the length of the baseline period (randomly assigned to be 7, 14 or 21 days), the treatment period varies between 63-77 days and contains 6-11 sessions. The intervention consists of 2-4 educational sessions in pain mechanisms and fear avoidance and 4-9 sessions of individually tailored intervention with graded exposure and reactivation to avoided physical activities. Intervention will take place from one time per week to one time every two weeks, 30-60 minutes per session. Number of treatment sessions will depend on when the individual participants' goals are considered reached. If necessary, given the participants consent, their legal guardians will be invited to attend the sessions.

06

What researchers measure

Primary outcomes

  1. Activity engagement change

    Change in self-rated activity engagement. Numerical Rating Scale, range 0-6 (1 question: lower values, worse outcome, 1 question: Lower values, better outcome )

    Time frame: repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84 days). 7 days assessment 6 months after terminated intervention

  2. Symptom distress change

    Change in self-rated distress about symptoms. Numerical Rating Scale, range 0-6 (3 questions, higher values, worse outcome)

    Time frame: repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84 days). 7 days assessment 6 months after terminated intervention.

Secondary outcomes

  1. Functional Disability Inventory (FDI) change

    Change in functional disability. Descriptive Rating Scale, range 0-64 (higher values, worse outcome)

    Time frame: baseline, after treatment phase B (12 weeks), 6 months after terminated intervention

  2. Center of Epidemiological Studies Depression Scales for Children (CES-DC) change

    Change in depressive symptoms. Descriptive Rating Scale, range 0-60 (higher values, worse outcome)

    Time frame: baseline, after treatment phase B (12 weeks), 6 months after terminated intervention

  3. The Pediatric Quality of Life Acute version (PedsQL) PedsQL™

    Change in quality of life. Descriptive Rating Scale, range 0-92 (higher values, worse outcome)

    Time frame: baseline, after treatment phase B (12 weeks), 6 months after terminated intervention

  4. Change in psychological distress

    Change in self-related symptoms of psychological distress. Numerical Rating Scale, range 0-6 (3 questions, higher values, worse outcome)

    Time frame: repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84days). 7 days assessment 6 months after terminated assessment.

  5. Pain change

    Change in self-related pain symptoms. Numerical Rating Scale range 0-6 (higher values, worse outcome)

    Time frame: repeated daily through phase A (randomly assigned to be 7, 14 or 21 days) and treatment phase B (9-11 weeks). Total time frame of assessment is 12 weeks (84days). 7 days assessment 6 months after terminated assessment.

  6. Fear of Pain Questionnaire Children Short-form (FOPQ-C SF) change

    Change in fear of pain. Descriptiv Rating Scale, range 0-40 (higher values worse outcome)

    Time frame: baseline, after treatment phase B (12 weeks), 6 months after terminated intervention

  7. The Photograph Series of Daily Activities for youth (PHODA) change - short

    Change in percieved harmfulness. Photographs with 50 activities, rated on a Subjective Self-rating Scale, range 0-100mm/item (higher values, worse outcome)

    Time frame: First session after baseline (randomly assigned to be 7, 14 or 21 days), after treatment phase B (12 weeks)

Other outcomes

  1. Treatment Inventory of Costs in Patients with psychiatric disorders (Tic-P), medical resources

    Change in use of medical resources. Dichotomous scale completed by open ended answers if answer is yes.

    Time frame: baseline, 12 weeks, 6 months after terminated intervention

  2. Treatment Inventory of Costs in Patients with psychiatric disorders (Tic-P), school absence

    Change in school abcense. Dichotomous scale completed by open ended answers if answer is yes. One question is completed by one question with Numerical Rating Scale 1-10 (higher values, worse outcome) if answer is yes.

    Time frame: baseline, 12 weeks, 6 months after terminated intervention

  3. Accelerometer

    Change in physical activity, digital device counting steps

    Time frame: 7 days of the first week of baseline (randomly assigned to be 7, 14 or 21 days). 7 days assessment 6 months after terminated assessment.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Nov 2026, 26 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 26 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2024
First posted
May 13, 2024
StartActual
Sep 23, 2024
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 2026
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06410963
Lead sponsor
Örebro University, Sweden
Responsible party
Sponsor
First posted
May 13, 2024
Start date
Sep 23, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 14, 2026

Study contacts

Katja Boersma, PhD
principal investigator · Örebro University, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion